Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 174   

Articles published

GSK 1,485.00 +6.50 (0.44%)
price chart
3 Black Friday Bargains: Barclays PLC, GlaxoSmithKline plc And Tesco PLC
Falling pharmaceuticals and vaccine sales in the US, disappointments in its consumer healthcare division, and the threat of further action over the Chinese bribery scandal have painted 2014 black for Glaxo. But unlike the bankers, I reckon it will ...
Related articles »  
Which Company Suits Your Portfolio: AstraZeneca plc Or GlaxoSmithKline plc ?
Pharmaceutical companies make great investments due to their defensive nature and reliable dividend payouts. The FTSE 100′s two pharma giants, AstraZeneca (LSE:AZN) (NYSE: AZN.
Related articles »  
Forget About 2015: Why GlaxoSmithKline plc Should Enjoy Stunning Long-Term ...
Like the rest of the pharmaceuticals sector, GlaxoSmithKline has seen sales of key drugs fall through the floor in recent years, as the entry of generic rivals has eaten away at group sales in established markets.
Is It Time To Buy GlaxoSmithKline plc?
While the point I discussed above, coupled with the restructuring that's going on at Glaxo, makes the company look cheap at current levels, you can't afford to base your portfolio solely on the company.
Related articles »  
Could You Double Your Money With GlaxoSmithKline plc?
GSK's share price rise represents a compound annual growth rate (CAGR) of 3.3%. Earnings per share (EPS) have increased at a CAGR of just 1.4%, with the remainder of the share price rise coming from an increase in the price-to-earnings (P/E) ratio.
Related articles »  
GlaxoSmithKline plc Earns Buy Rating from Beaufort Securities (GSK)
Analysts at BNP Paribas initiated coverage on shares of GlaxoSmithKline plc in a research note on Tuesday. They set an �underperform� rating on the stock.
Beaufort Securities Reaffirms Buy Rating for GlaxoSmithKline plc (GSK)  Mideast Time
Morningstar Issues "A+" Credit Rating to GlaxoSmithKline plc (GSK)  sleekmoney
Related articles »  
GlaxoSmithKline plc Is Best In Class When It Comes To Affordable Medicine
Moreover, Glaxo is rapidly closing in on producing the world's first malaria vaccine, after filing for regulatory approval in July.
Related articles »  
Will GlaxoSmithKline plc Be Back To Growth By 2016?
Investing in steadily-growing companies like GlaxoSmithKline has made it possible for many an investor to achieve millionaire status -- and you can do it too.
GlaxoSmithKline plc Stock Rating Reaffirmed by JPMorgan Chase & Co. (GSK)  Ticker Report
Credit Suisse Reiterates Underperform Rating for GlaxoSmithKline plc (GSK)  sleekmoney
Related articles »  
Major Ebola Breakthrough As GlaxoSmithKline (GSK) Reports Promising ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced promising results from Phase I trials of its Ebola vaccine Wednesday, effectively coming out ahead of competitors.
GlaxoSmithKline Ebola Vaccine Found Safe in Early Tests  Bloomberg
Related articles »  
Why Forecasts Are Falling At GlaxoSmithKline plc
The company's quarterly figures this year have been falling short of expectations too, and at the first-half stage Glaxo reported a 12% fall in core EPS at constant exchange rates, with the statutory reported figure down 14% - at real exchange rates ...